SCHEMBL2223065

SCHEMBL2223065

COc1ccnc2ccc(Cc3nn(-c4cnn(C)c4)ccc3=O)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 12/20 0.40
FLT3 P36888 2/20 0.35
CSF1R P07333 1/20 0.35
PDGFRB P09619 1/20 0.35
KDR P35968 1/20 0.35
PDPK1 O15530 2/20 0.34
AXL P30530 1/20 0.34
CCNC P24863 1/20 0.34
CDK8 P49336 1/20 0.34
MST1R Q04912 1/20 0.34
HDAC1 Q13547 1/20 0.34
PDE10A Q9Y233 2/20 0.34
PDE2A O00408 1/20 0.34
ABCC4 O15439 1/20 0.34
USP2 O75604 1/20 0.34
PDE5A O76074 1/20 0.34
ABCB11 O95342 1/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL368067 0.92 MET (0.39) METFLT3CSF1RPDGFRBKDR
SCHEMBL359286 0.86 MET (0.39) METFLT3CSF1RPDGFRBKDR
SCHEMBL358937 0.86 MET (0.37) METFLT3CSF1RPDGFRBKDR
SCHEMBL2223043 0.82 MET (0.52) METPDE10A
SCHEMBL13274704 0.79 KDM4C (0.36) METCCNCCDK8
SCHEMBL369336 0.79 MET (0.39) METFLT3CCNCCDK8HDAC1
SCHEMBL368727 0.79 MET (0.41) METFLT3HDAC1
SCHEMBL359822 0.77 MET (0.36) METCSF1RPDGFRBKDRAXL
SCHEMBL13275211 0.77 MET (0.41) MET
SCHEMBL2266767 0.76 MET (0.43) MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2515657-A1 TYROSINE KINASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2012-10-31 EP claimed
US-20120264735-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-10-18 US claimed
WO-2011084402-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-07-14 WO claimed
EP-2515657-A1 TYROSINE KINASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2012-10-31 EP disclosed
US-20120264735-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-10-18 US disclosed
US-20120264735-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-10-18 US disclosed
US-20120264735-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-10-18 US disclosed
WO-2011084402-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264735-A1 TYROSINE KINASE INHIBITORS ABL1, MET, ERBB2 MET 2/4885FLT3 15/4885CSF1R 402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.